EUVIMEDEUVIMED entdecken
Multizentrische Studie

Refining BCG ‐failure classifications in non‐muscle‐invasive bladder cancer

Aleksander Ślusarczyk iD, Pietro Scilipoti, Roberto Contieri iD, Wojciech Krajewski, Francesco Claps iD, José Daniel Subiela iD, Laura S Mertens iD, Keiichiro Mori iD, Elisabeth Grobet-Jeandin, Jorge Caño Velasco, Karl Tully iD, Francesco Soria iD und 20 weitere

BJU International · 2026-06 · 137 (6) · 1076-1087

DOI: 10.1111/bju.70231 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 19.03.2026. Verfasst von Aleksander Ślusarczyk und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, BCG Vaccine, Adjuvants, Immunologic, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To validate International Bladder Cancer Group (IBCG) definitions of Bacillus Calmette‐Guérin (BCG)‐unresponsive and BCG‐exposed non‐muscle‐invasive bladder cancer (NMIBC) and assess prognostic heterogeneity across various BCG‐failure types. Patients and Methods From a multicentre international cohort of 3806 BCG‐treated patients, 591 who developed high‐grade NMIBC recurrence following BCG between 2003 and 2024 were included. Progression‐free survival (PFS) was the primary endpoint; cancer‐specific (CSM) and overall mortality (OM) were secondary endpoints. Cumulative incidence functions, competing‐risk models and multivariable Cox regression were used.

Results

Patients with BCG‐unresponsive and BCG‐exposed disease showed similar PFS, CSM, and OM (all P > 0.05). When stratified into five subgroups, prognosis varied: 5‐year progression rates were 29% for BCG‐unresponsive, 32.5% for late relapse (between 6 and 24 months) after adequate BCG, 30% for BCG‐exposed with inadequate BCG (24 months since last BCG) ( P < 0.01). In multivariable analysis, BCG‐exposed after inadequate BCG (subdistribution hazard ratio [sHR] 3.42, 95% confidence interval [CI] 1.33–8.84), late relapse (sHR 3.74, 95% CI 1.59–8.78), and BCG‐unresponsive (sHR 2.34, 95% CI 1.00–5.44) were associated with higher progression risks compared to very late relapse. Limitations include retrospective design and treatment heterogeneity.

Conclusions

Under IBCG definitions, BCG‐unresponsive and BCG‐exposed NMIBC have similarly poor outcomes. A refined classification reveals prognostic heterogeneity, with late relapses after adequate BCG demonstrating outcomes comparable to BCG‐unresponsive, and very late relapses conferring better prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-Muscle Invasive Bladder NeoplasmsBCG VaccineAdjuvants, ImmunologicUrinary Bladder NeoplasmsHumansFemaleMaleAgedPrognosisNeoplasm Recurrence, LocalTreatment FailureMiddle AgedProgression-Free SurvivalRetrospective Studies

Stichwörter der Autor:innen

BCG failureBCG therapyBCG‐unresponsive tumourNMIBCprogressionsurvivalurinary neoplasm of the bladderurothelial cancer

Substanzen

BCG VaccineAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
  • Department of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Urology, National Cancer Institute, IRCCS Fondazione G. Pascale, Naples, Italy.
  • Department of Urology and Oncologic Urology, Wrocław Medical University, Wrocław, Poland.
  • Oncological Urology, Veneto Institute of Oncology IRCCS, Padua, Italy.

ORCID-Profile: Aleksander Ślusarczyk, Roberto Contieri, Francesco Claps, José Daniel Subiela, Laura S Mertens, Keiichiro Mori, Karl Tully, Francesco Soria, Andrea Mari, Ekaterina Laukhtina, Luca Afferi, Simone Albisinni, Andrea Gallioli, Francesco Del Giudice, Marco Moschini

Zitieren

APA

Ślusarczyk, A., Scilipoti, P., Contieri, R., Krajewski, W., Claps, F., Subiela, J. D., Mertens, L. S., Mori, K., Grobet-Jeandin, E., Velasco, J. C., Tully, K., Soria, F., Duran, P. D. O., Puentedura, A. L., Lijnen, R. A. G., Longoni, M., Marcq, G., Mari, A., Laukhtina, E., …, & Urothelial Carcinoma Working Group (2026). Refining BCG ‐failure classifications in non‐muscle‐invasive bladder cancer. BJU International, 137(6), 1076-1087. https://doi.org/10.1111/bju.70231

Vancouver

Ślusarczyk A, Scilipoti P, Contieri R, Krajewski W, Claps F, Subiela JD, et al. Refining BCG ‐failure classifications in non‐muscle‐invasive bladder cancer. BJU International. 2026;137(6):1076-1087. doi:10.1111/bju.70231

BibTeX
@article{lusarczyk2026,
  author = {Ślusarczyk, Aleksander and Scilipoti, Pietro and Contieri, Roberto and Krajewski, Wojciech and Claps, Francesco and Subiela, José Daniel and Mertens, Laura S and Mori, Keiichiro and Grobet-Jeandin, Elisabeth and Velasco, Jorge Caño and Tully, Karl and Soria, Francesco and Duran, Pedro Del Olmo and Puentedura, Alfonso Lafuente and Lijnen, Renee A G and Longoni, Mattia and Marcq, Gautier and Mari, Andrea and Laukhtina, Ekaterina and Afferi, Luca and Albisinni, Simone and Gallioli, Andrea and Del Giudice, Francesco and Boorjian, Stephen A and Briganti, Alberto and Shariat, Shahrokh F and Gontero, Paolo and Radziszewski, Piotr and Moschini, Marco and Pradere, Benjamin and European Association of Urology‐Young Academic Urologists (EAU‐YAU), European Association of Urology‐Young Academic Urologists (EAU‐YAU) and Urothelial Carcinoma Working Group, Urothelial Carcinoma Working Group},
  title = {Refining BCG ‐failure classifications in non‐muscle‐invasive bladder cancer},
  journal = {BJU International},
  year = {2026},
  volume = {137},
  number = {6},
  pages = {1076--1087},
  doi = {10.1111/bju.70231}
}
Kostenlos starten →